Press release

Results of the Combined General Meeting of May 28, 2020

All ordinary and extraordinary resolutions have been adopted

Paris, (France), Cambridge (Massachusetts, United States), May 28, 2020, 6:00 p.m. CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, amongst which neuromuscular diseases, today announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting.

Biophytis' combined General Meeting took place today behind closed doors, due to measures imposed in the context of the COVID-19 pandemic. The 1,453 shareholders taking part in the vote owned collectively 9,779,269 shares, i.e. a quorum of 23.57% and 20.87% of the voting rights.

The shareholders approved by a very large majority all the 21 resolutions within the competence of the Combined General Meeting, in particular those ratifying the unconsolidated and consolidated accounts for fiscal year 2019 and the allocation of profit for the fiscal year ended December 31, 2019 as well as extraordinary resolutions.

Stanislas Veillet, President and CEO of Biophytis, said: *"I am very pleased that all the resolutions of the Combined General Meeting were approved by a very large majority. I would like to warmly thank all 1,453 shareholders for their exceptional commitment that made it possible for us to hold this General Meeting and for their confidence in Biophytis by supporting by more than 90% each resolution put to the vote."*

The results of the votes of the combined General Meeting will be available on Biophytis' website from June 1, 2020, under the section - Investors - Regulated Information.
(www.biophytis.com/en/action/document/) .

****

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development (MYODA) in H2 2020.

Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus). The Company has received approval from the Belgian Regulatory Authority (FAMHP) to begin the Phase 2/3 clinical trial (COVA) with Sarconeos (BIO101), evaluating it as a potential treatment for respiratory failure associated with Covid-19. The Company also filed clinical trial applications with the FDA in the US, MHRA in the UK and the French regulatory agency, ANSM in France.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. While the Company considers its projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements. For a description of the risks and uncertainties likely to affect the results, BIOPHYTIS' financial position, performance or achievements and thus cause a change from the forward-looking statements, please refer to the "Risk Factors" section of the Company's 2018 Annual Report available on BIOPHYTIS website (www.biophytis.com).

This press release, and the information contained in it, does not constitute an offer to sell or subscribe, nor the solicitation of a purchase or subscription order, of BIOPHYTIS shares in any country. The elements contained in this communication may contain forward-looking information involving risks and uncertainties. The Company's actual achievements may differ materially from those anticipated in this information due to different risk and uncertainty factors. This press release was written in French and English; If there is a difference between the texts, the French version will prevail.

Biophytis Contact for Investor Relations

Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact

Citigate Dewe Rogerson
Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +44 (0) 20 7638 9571 / +33 (0)1 55 30 70 91